An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors

A Phase 1 A/B Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AbGn-7 Therapy Alone and in Combination With the FOLFOX7 Treatment Regimen in Patients With Advanced Solid Tumors

The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in combination with FOLFOX7 in patients with chemo-naive/chemo-refractory recurrent, locally advanced or metastatic gastric cancer.

Study Overview

• Status: Completed
• Conditions: Gastric Cancer; Solid Tumor of Epithelial Origin
• Intervention / Treatment: Drug: AbGn-7; Drug: AbGn-7

Detailed Description

Monoclonal antibodies, alone or in combination with chemotherapeutic agents, have been proven to be effective treatment for many malignant diseases in human. Antibodies can mediate cytotoxicity through complement dependent cytotoxicty (CDC), antibody dependent cell mediated cytotoxicity (ADCC) or apoptosis.

AbGn-7 was identified based on its direct killing (apoptosis-inducing) activities towards cancer cells expressing its epitope. In vitro data also demonstrated its ability to elicit CDC and ADCC. The in vivo xenograft study of AbGn-7 demonstrated that AbGn-7 alone or in combination with chemotherapeutic agents successfully suppressed the growth of gastric, pancreatic, and colorectal tumours. The NHP study proved the safety profile of AbGn-7. The present Phase 1 clinical study is designed to evaluate the safety and tolerability of AbGn-7 alone in patients with solid tumors of epithelial origin (Phase 1a) and in combination with a current chemotherapeutic regimen FOLFOX7 in patients with recurrent, locally advanced or metastatic gastric carcinoma (Phase 1b).

• Study Type: Interventional
• Enrollment (Actual): 13
• Phase: Phase 1

Contacts and Locations

Study Locations

• Taiwan
  • Taipei, Taiwan, 104
    • Mackay Memorial Hospital
  • Taipei, Taiwan, 104
    • National Taiwan University Hospital
• United States
  • Pennsylvania
    • Rockledge, Pennsylvania, United States, 19046
      • Fox Chase Cancer Center
  • Texas
    • San Antonio, Texas, United States, 78229
      • The University of Texas Health Science Center-CTRC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. must provide written informed consent.
2. must be ≥18 years of age, either sex and of any race/ethnicity.
3. Phase 1a: must have a histologically or cytologically confirmed advanced malignant solid tumor of epithelial origin and must have failed on previous chemotherapy. Phase 1b: must have a histologically or cytologically confirmed, recurrent, locally advanced or metastatic gastric cancer with measurable disease; must be chemo-naïve or must have failed on previous chemotherapy; must not have received an oxaliplatin-based chemotherapeutic regimen or monoclonal antibody therapy.
4. must have an Eastern Cooperative Oncology Group Performance Status of ≤2.
5. must have adequate hematological, renal and liver functions within 3 weeks prior to first study drug administration as evidenced by: a) Absolute neutrophil count ≥1.5 x 109/L, b) Hemoglobin ≥90 g/L (≥80 g/L for patients with documented renal cell carcinoma), c) Platelet count ≥100 x 109/L, d) Serum creatinine ≤1.5 x upper limit of normal ULN or a calculated creatinine clearance ≥60 mL/minute, e) Total bilirubin <1.5 x ULN, except for patients with documented Gilbert's disease, f) AST/SGOT and ALT/SGPT < 2.5 x ULN, or, in the presence of documented liver metastases, ≤5 x ULN.
6. must be able to adhere to dose and visit schedules.
7. Each female patient of childbearing potential must agree to use a medically accepted method of contraception or to abstain from sexual intercourse and each male patient must agree to use a medically accepted method of contraception or to abstain from sexual intercourse during the study and for 60 days after stopping the study drug.
8. A life expectancy of at least 3 months.
9. Available tumor tissue in the form of unstained slides for determination of AbGn-7 epitope expression (optional for Phase 1a, obligatory for Phase 1b). Patients without archival/banked tumor tissue obtained at the time of initial diagnosis must have a biopsy performed according to institutional guidelines prior to the initiation of treatment.

Exclusion Criteria:

1. No current treated or untreated leptomeningeal metastasis or a metastatic CNS lesion.
2. For Phase 1a, patients should not have received chemotherapy within 30 days prior to initiation of AbGn-7 therapy. For Phase 1b, patients should not have received oxaliplatin-based chemotherapy or monoclonal antibody therapy for their gastric cancer prior to enrollment.
3. Have note received radiation therapy within 3 weeks prior to first study drug administration and must have adequately recovered from any associated toxicity and/or complications of this intervention.
4. Have not undergone major surgery within 3 weeks prior to the first study drug administration and must have adequately recovered from the toxicity and/or complications of these interventions.
5. No current human immunodeficiency virus (HIV) infection or a current HIV-related malignancy.
6. No current active hepatitis B or C.
7. No any serious or uncontrolled infection.
8. No uncontrolled diabetes mellitus, defined as a HbA1c of ≥7.5% in a patient with documented diabetes mellitus.
9. No any of the following within 6 months prior to first study drug administration: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, clinically significant cardiac dysrhythmia or clinically significant ECG abnormality, cerebrovascular accident or transient ischemic attack, or seizure disorder.
10. No persistent, unresolved NCI CTCAE Grade ≥2 drug-related toxicity associated with previous chemotherapy.
11. Not participating in any other clinical study with a potentially therapeutic agent, or have not received another investigational product within 21 days.
12. No any clinically significant condition or situation which would interfere with the study evaluations or optimal participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AbGn-7 phase 1a cohort 1	Drug: AbGn-7; Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Drug: AbGn-7; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Experimental: AbGn-7 phase 1a cohort 2	Drug: AbGn-7; Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Drug: AbGn-7; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Experimental: AbGn-7 phase 1a cohort 3	Drug: AbGn-7; Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Drug: AbGn-7; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Experimental: AbGn-7 phase 1b cohort 1	Drug: AbGn-7; Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Drug: AbGn-7; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Experimental: AbGn-7 phase 1b cohort 2	Drug: AbGn-7; Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks; Drug: AbGn-7; Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety will be assessed by analysis of adverse event, clinical laboratory tests and physical examination	10 Weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Pharmacokinetics will be assessed at 3 different dose levels in phase 1a and at 2 dose levels in phase 1b	12 Weeks
Serum anti-drug antibodies will be assessed at 3 different dose levels in phase 1a and at 2 dose levels in phase 1b	12 weeks
Tumor response rate by Response Evaluation Criteria in Solid Tumors (RECIST)	10 weeks

Collaborators and Investigators

• Sponsor: AbGenomics B.V Taiwan Branch
• Investigators: Principal Investigator: Devalingham Mahalingam, MD, The University of Texas Health Science Center-CTRC; Principal Investigator: Anthony Olaszanski, MD, RPh, Fox Chase Cancer Center; Principal Investigator: Kuen-Hui Yeh, MD, National Taiwan University Hospital; Principal Investigator: Ruey-Kuen Hsieh, MD, Mackay Memorial Hospital

Study record dates

Study Major Dates

• Study Start: November 1, 2011
• Primary Completion (Actual): January 1, 2013
• Study Completion (Actual): January 1, 2013

Study Registration Dates

• First Submitted: November 2, 2011
• First Submitted That Met QC Criteria: November 4, 2011
• First Posted (Estimate): November 8, 2011

Study Record Updates

• Last Update Posted (Estimate): June 23, 2015
• Last Update Submitted That Met QC Criteria: June 22, 2015
• Last Verified: June 1, 2015

More Information

Terms related to this study

• Keywords: Gastric Cancer; Oncology; Advanced Solid Tumor; monoclonal Antibody
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms
• Other Study ID Numbers: AbGenomics-2010.007.01